Special Counsel Finds No Wrongdoing in Whistleblower Probe
This article was originally published in The Gray Sheet
Executive Summary
A three-year investigation into whistleblower allegations that FDA had improperly cleared several devices has ended with a Special Counsel finding that the claims were unfounded.